As the small molecules revolution continues to make “undruggable” targets “druggable”, the 5th TPD & Induced Proximity Summit Europe offered 3 days of jam-packed content.
We addressed some of the industry's biggest challenges including, but not limited to:
Enhancing Oral Bioavailability of PROTACs:
Exploring innovative strategies to improve the oral bioavailability of PROTACs, ensuring effective delivery and patient exposure
Developing Non-Degrading Proximity Therapeutics:
Gaining insights into the development of non-degrading proximity therapeutics, realising the true therapeutic potential of small molecules and targeting novel diseases
Advancing Molecular Glue Discovery:
Delving into the latest techniques and platforms for accelerating and optimising molecular glue discovery to target previously undruggable proteins
Innovating Non-Ubiquitination and Non-Cytosolic Degraders:
Learning about cutting-edge approaches for lysosomal degraders as well as surface and ECM protein degradation, offering new avenues for therapeutic intervention and filling unmet needs
4 Reasons You Shouldn't Have Missed The World's Leading European TPD And Induced Proximity Event:
Translating your targeted protein degraders into the clinic with insights on ADME, dosing, and patient selection challenges from Merck Healthcare KGaA, Foghorn Therapeutics, and Astellas Pharmaceuticals
Unlocking previously untargeted disease targets and enable their degradation by expanding to effectors beyond traditional E3 ligases with pioneering discoveries by Phoremost, BPG Bio, and Innoxtal
Enabling novel therapeutic interventions such as targeting
extracellular matrix and surface proteins and go beyond degradation with innovative molecules shared by Laigo Bio, Rapafusyn Pharmaceuticals
and Draupnir Bio
Accelerating PROTAC and molecular glue discovery by integrating AI for predicting surface complementarities, PK-PD profiles, and ternary structures developed by Vant AI, Sibylla Biotech and Ternary Therapeutics
Why Should You Have Attended the Summit?
If you were seeking to connect with major European decision-makers, experts, and key opinion leaders in, including CXOs, VPs, and Directors leading Protein Degradation, Chemical Biology, and Medicinal Chemistry teams in biopharma, then this was the summit for you!
You could have joined your peers across 3 days to propel the field forward and explore the advances made by the European TPD community. This gathering of drug developers, small molecule experts, and academic thought leaders offered the perfect opportunity to assess your pipeline progress, learn from your peers’ case studies and unlock the full potential of induced proximity therapeutics.
Companies on the 2025 Program:
What Your Peers Had To Say:
